Factors affecting bone marrow toxicity following administration of carboplatin and paclitaxel in patients with non-small cell lung cancer

Apar Kishor P Ganti, Fausto R. Loberiza, Anne Kessinger

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Despite accounting for more than half of the patients diagnosed with non-small cell lung cancer (NSCLC), only 20% of elderly patients receive chemotherapy. One reason for withholding systemic therapy is the concern for an increased incidence of side-effects, especially cytopenia from bone marrow toxicity. Limited data exist regarding specific factors that affect blood count nadirs following chemotherapy. Patients and Methods: A retrospective chart review was conducted of chemotherapy-naïve patients who had received standard doses of carboplatin and paclitaxel for NSCLC. Hemoglobin levels, total white blood cell counts (WBC) and platelet counts before each chemotherapy cycle and nadir counts following each cycle were obtained. Wilcoxon test and Chi-square test were used for univariate comparisons of patient characteristics and unpaired t-test for hematological parameters. Multivariate analyses of change over time in the hematological parameters by age groups were performed using mixed models while adjusting for other clinical factors. Results: Of the 91 consecutive patients identified from the medical records between 1992 and 2007, 37 (41%) were <60 years old at diagnosis. Pre-chemotherapy and nadir values for hemoglobin, WBC and platelet counts did not vary by age over time. The nadir values correlated with the corresponding pre-chemotherapy values. Both the pre-chemotherapy and nadir values showed a decreasing trend with increasing numbers of chemotherapy cycles administered. Conclusion: Age does not affect the nadir counts of hemoglobin, WBC and platelets following administration of carboplatin and paclitaxel for NSCLC. Pre-chemotherapy blood counts are more important determinants of hematologic toxicity following administration of carboplatin and paclitaxel for advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)1365-1369
Number of pages5
JournalAnticancer Research
Volume30
Issue number4
StatePublished - Apr 1 2010

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Bone Marrow
Drug Therapy
Leukocyte Count
Hemoglobins
Blood Platelets
Platelet Count
Hematologic Tests
Chi-Square Distribution
Medical Records
Multivariate Analysis
Age Groups
Incidence

Keywords

  • Age
  • Carboplatin
  • Chemotherapy
  • Hematologic toxicity
  • Non-small cell lung cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Factors affecting bone marrow toxicity following administration of carboplatin and paclitaxel in patients with non-small cell lung cancer. / Ganti, Apar Kishor P; Loberiza, Fausto R.; Kessinger, Anne.

In: Anticancer Research, Vol. 30, No. 4, 01.04.2010, p. 1365-1369.

Research output: Contribution to journalArticle

@article{178b0e3d4d464129bcc0a14644f93db9,
title = "Factors affecting bone marrow toxicity following administration of carboplatin and paclitaxel in patients with non-small cell lung cancer",
abstract = "Background: Despite accounting for more than half of the patients diagnosed with non-small cell lung cancer (NSCLC), only 20{\%} of elderly patients receive chemotherapy. One reason for withholding systemic therapy is the concern for an increased incidence of side-effects, especially cytopenia from bone marrow toxicity. Limited data exist regarding specific factors that affect blood count nadirs following chemotherapy. Patients and Methods: A retrospective chart review was conducted of chemotherapy-na{\"i}ve patients who had received standard doses of carboplatin and paclitaxel for NSCLC. Hemoglobin levels, total white blood cell counts (WBC) and platelet counts before each chemotherapy cycle and nadir counts following each cycle were obtained. Wilcoxon test and Chi-square test were used for univariate comparisons of patient characteristics and unpaired t-test for hematological parameters. Multivariate analyses of change over time in the hematological parameters by age groups were performed using mixed models while adjusting for other clinical factors. Results: Of the 91 consecutive patients identified from the medical records between 1992 and 2007, 37 (41{\%}) were <60 years old at diagnosis. Pre-chemotherapy and nadir values for hemoglobin, WBC and platelet counts did not vary by age over time. The nadir values correlated with the corresponding pre-chemotherapy values. Both the pre-chemotherapy and nadir values showed a decreasing trend with increasing numbers of chemotherapy cycles administered. Conclusion: Age does not affect the nadir counts of hemoglobin, WBC and platelets following administration of carboplatin and paclitaxel for NSCLC. Pre-chemotherapy blood counts are more important determinants of hematologic toxicity following administration of carboplatin and paclitaxel for advanced NSCLC.",
keywords = "Age, Carboplatin, Chemotherapy, Hematologic toxicity, Non-small cell lung cancer, Paclitaxel",
author = "Ganti, {Apar Kishor P} and Loberiza, {Fausto R.} and Anne Kessinger",
year = "2010",
month = "4",
day = "1",
language = "English (US)",
volume = "30",
pages = "1365--1369",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Factors affecting bone marrow toxicity following administration of carboplatin and paclitaxel in patients with non-small cell lung cancer

AU - Ganti, Apar Kishor P

AU - Loberiza, Fausto R.

AU - Kessinger, Anne

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Background: Despite accounting for more than half of the patients diagnosed with non-small cell lung cancer (NSCLC), only 20% of elderly patients receive chemotherapy. One reason for withholding systemic therapy is the concern for an increased incidence of side-effects, especially cytopenia from bone marrow toxicity. Limited data exist regarding specific factors that affect blood count nadirs following chemotherapy. Patients and Methods: A retrospective chart review was conducted of chemotherapy-naïve patients who had received standard doses of carboplatin and paclitaxel for NSCLC. Hemoglobin levels, total white blood cell counts (WBC) and platelet counts before each chemotherapy cycle and nadir counts following each cycle were obtained. Wilcoxon test and Chi-square test were used for univariate comparisons of patient characteristics and unpaired t-test for hematological parameters. Multivariate analyses of change over time in the hematological parameters by age groups were performed using mixed models while adjusting for other clinical factors. Results: Of the 91 consecutive patients identified from the medical records between 1992 and 2007, 37 (41%) were <60 years old at diagnosis. Pre-chemotherapy and nadir values for hemoglobin, WBC and platelet counts did not vary by age over time. The nadir values correlated with the corresponding pre-chemotherapy values. Both the pre-chemotherapy and nadir values showed a decreasing trend with increasing numbers of chemotherapy cycles administered. Conclusion: Age does not affect the nadir counts of hemoglobin, WBC and platelets following administration of carboplatin and paclitaxel for NSCLC. Pre-chemotherapy blood counts are more important determinants of hematologic toxicity following administration of carboplatin and paclitaxel for advanced NSCLC.

AB - Background: Despite accounting for more than half of the patients diagnosed with non-small cell lung cancer (NSCLC), only 20% of elderly patients receive chemotherapy. One reason for withholding systemic therapy is the concern for an increased incidence of side-effects, especially cytopenia from bone marrow toxicity. Limited data exist regarding specific factors that affect blood count nadirs following chemotherapy. Patients and Methods: A retrospective chart review was conducted of chemotherapy-naïve patients who had received standard doses of carboplatin and paclitaxel for NSCLC. Hemoglobin levels, total white blood cell counts (WBC) and platelet counts before each chemotherapy cycle and nadir counts following each cycle were obtained. Wilcoxon test and Chi-square test were used for univariate comparisons of patient characteristics and unpaired t-test for hematological parameters. Multivariate analyses of change over time in the hematological parameters by age groups were performed using mixed models while adjusting for other clinical factors. Results: Of the 91 consecutive patients identified from the medical records between 1992 and 2007, 37 (41%) were <60 years old at diagnosis. Pre-chemotherapy and nadir values for hemoglobin, WBC and platelet counts did not vary by age over time. The nadir values correlated with the corresponding pre-chemotherapy values. Both the pre-chemotherapy and nadir values showed a decreasing trend with increasing numbers of chemotherapy cycles administered. Conclusion: Age does not affect the nadir counts of hemoglobin, WBC and platelets following administration of carboplatin and paclitaxel for NSCLC. Pre-chemotherapy blood counts are more important determinants of hematologic toxicity following administration of carboplatin and paclitaxel for advanced NSCLC.

KW - Age

KW - Carboplatin

KW - Chemotherapy

KW - Hematologic toxicity

KW - Non-small cell lung cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=77953765546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953765546&partnerID=8YFLogxK

M3 - Article

C2 - 20530454

AN - SCOPUS:77953765546

VL - 30

SP - 1365

EP - 1369

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -